Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
LPTX

LPTX - Leap Therapeutics Inc Stock Price, Fair Value and News

2.05USD-0.06 (-2.84%)Market Closed

Market Summary

LPTX
USD2.05-0.06
Market Closed
-2.84%

LPTX Stock Price

View Fullscreen

LPTX RSI Chart

LPTX Valuation

Market Cap

78.4M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

75.76

EV/EBITDA

-0.35

Price/Free Cashflow

-1.68

LPTX Price/Sales (Trailing)

LPTX Profitability

EBT Margin

-7394.55%

Return on Equity

-112.66%

Return on Assets

-92.08%

Free Cashflow Yield

-59.37%

LPTX Fundamentals

LPTX Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-9.56%

Rev. Growth (Qtr)

-38.5%

LPTX Earnings

Earnings (TTM)

-53.4M

Earnings Growth (Yr)

66.99%

Earnings Growth (Qtr)

-10.87%

Breaking Down LPTX Revenue

Last 7 days

-12.8%

Last 30 days

5.7%

Last 90 days

-26.8%

Trailing 12 Months

-32.3%

How does LPTX drawdown profile look like?

LPTX Financial Health

Current Ratio

5.38

LPTX Investor Care

Shares Dilution (1Y)

220.44%

Diluted EPS (TTM)

-1.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20232.3M2.0M1.9M1.1M
20221.4M1.6M1.8M2.1M
20211.8M1.8M2.9M1.2M
20202.2M2.5M2.8M1.8M
20191.0M1.3M1.6M1.9M
20181.5M1.2M995.8K756.0K
20172.8M2.4M2.1M1.7M
20160003.1M

Tracking the Latest Insider Buys and Sells of Leap Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 26, 2024
mirabelli christopher
acquired
-
-
5,000
chairman of the board
Jan 26, 2024
lawlor augustine
acquired
-
-
5,000
chief operating officer
Jan 26, 2024
onsi douglas e
acquired
-
-
7,500
ceo,cfo,pres.,gc,treas.,&sec.
Jan 26, 2024
sirard cynthia
acquired
-
-
5,000
chief medical officer
Jan 26, 2024
o'mahony john mark
acquired
-
-
5,000
chief manufacturing officer
Mar 17, 2023
onsi douglas e
acquired
-
-
660,606
ceo,cfo,pres.,gc,treas.,&sec.
Sep 24, 2021
beigene, ltd.
bought
7,249,830
2.85
2,543,800
-
Dec 28, 2020
healthcare ventures viii, l.p.
sold
-
-
-2,618,410
-
Jun 22, 2020
perceptive advisors llc
bought
3,500,000
2.00
1,750,000
-
Feb 05, 2019
mirabelli christopher
bought
999,999
1.75
571,428
ceo, president, chairman

1–10 of 13

Which funds bought or sold LPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
TOMPKINS FINANCIAL CORP
unchanged
-
-84.00
235
-%
Jul 16, 2024
Key Client Fiduciary Advisors, LLC
added
22.25
-61,510
558,318
0.28%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
new
-
40,320
40,320
-%
May 15, 2024
ACUTA CAPITAL PARTNERS, LLC
unchanged
-
-525,936
942,082
0.61%
May 15, 2024
MARSHALL WACE, LLP
new
-
57,626
57,626
-%
May 15, 2024
683 Capital Management, LLC
unchanged
-
-668,251
1,197,000
0.09%
May 15, 2024
Tower Research Capital LLC (TRC)
added
113
4,710
17,468
-%
May 15, 2024
Rock Springs Capital Management LP
added
9.48
-1,026,770
2,425,750
0.06%
May 15, 2024
Squarepoint Ops LLC
new
-
71,873
71,873
-%
May 15, 2024
Samsara BioCapital, LLC
unchanged
-
-993,915
1,780,350
0.28%

1–10 of 45

Are Funds Buying or Selling LPTX?

Are funds buying LPTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LPTX
No. of Funds

Unveiling Leap Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 25, 2024
samsara biocapital, l.p.
6.4%
2,442,352
SC 13G
Apr 19, 2024
gilead sciences, inc.
13.9%
5,319,148
SC 13G
Feb 14, 2024
perceptive advisors llc
4.0%
1,068,497
SC 13G/A
Feb 14, 2023
perceptive advisors llc
6.8%
6,726,496
SC 13G/A
Feb 15, 2022
perceptive advisors llc
9.6%
8,476,496
SC 13G/A
Feb 14, 2022
hhlr advisors, ltd.
0%
0
SC 13G/A
Feb 11, 2022
artal international s.c.a.
4.5%
4e+06
SC 13G/A
Feb 10, 2022
eli lilly & co
3.5%
3,151,605
SC 13G/A
Sep 29, 2021
beigene, ltd.
13.2%
12,153,074
SC 13D/A
Feb 16, 2021
hillhouse capital advisors, ltd.
6.2%
3,716,240
SC 13G

Recent SEC filings of Leap Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 08, 2024
8-K
Current Report
May 23, 2024
EFFECT
EFFECT
May 23, 2024
424B3
Prospectus Filed
May 21, 2024
CORRESP
CORRESP
May 16, 2024
UPLOAD
UPLOAD
May 16, 2024
DEFA14A
DEFA14A
May 13, 2024
8-K
Current Report
May 13, 2024
10-Q
Quarterly Report
May 10, 2024
S-3
S-3
May 09, 2024
EFFECT
EFFECT

Peers (Alternatives to Leap Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Leap Therapeutics Inc News

Latest updates
MarketBeat14 Jul 202408:42 am
Yahoo Canada Shine On12 Jul 202407:50 pm

Leap Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-38.5%246,000400,000554,000298,000272,000775,000652,000587,000814,3331,041,6671,269,000375,000375,000839,500228,000375,000375,0001,794,000927,50061,00075,000
Operating Expenses0.0%14,825,00014,820,00014,833,00014,662,00042,726,00013,943,00015,288,00016,900,00010,632,00010,863,00012,515,00010,001,0009,547,0007,529,0007,883,0007,871,0006,756,0008,272,0007,923,0008,461,0008,795,000
  S&GA Expenses12.5%3,526,0003,135,0003,330,0003,558,0003,784,0002,909,0003,186,0002,855,0002,848,0002,793,0002,438,0002,795,0002,740,0002,428,0002,514,0002,521,0002,153,0002,604,0002,151,0002,325,0002,005,000
  R&D Expenses-3.3%11,299,00011,685,00011,503,00011,104,00038,942,00011,034,00012,102,00014,045,0007,784,0008,070,00010,077,0007,206,0006,807,0005,101,0005,369,0005,350,0004,603,0005,668,0005,772,0006,136,0006,790,000
EBITDA Margin0.0%-73.93-73.93-28.64-27.23-23.79-26.51-21.98-24.74-28.30-33.07-12.75-17.80---------
Interest Expenses------5,00011,00017,00021,0002,0009,00016,00014,000-3,00017,00013,00012,0002,0005,0009,0007,000
Earnings Before Taxes-----------10,812,000-11,139,000-9,526,000-9,134,000-6,712,000-7,057,000-6,516,000-7,231,000-7,999,000-7,935,000-8,366,000-8,603,000
EBT Margin0%-73.95-73.95-28.67-27.27-23.82-26.55-22.01-24.79-28.35-33.12-12.77-17.84---------
Net Income-10.9%-13,820,000-12,465,000-13,696,000-13,390,000-41,863,000-12,102,000-15,094,000-17,024,000-10,376,000-10,788,000-11,139,000-9,526,000-9,134,000-6,710,000-7,057,000-6,516,000-7,231,000-7,996,000-7,935,000-8,366,000-8,603,000
Net Income Margin34.4%-48.48-73.95-42.68-41.29-37.66-26.62-28.88-30.10-29.21-33.11-12.77-17.84---------
Free Cashflow-49.5%-15,516,000-10,380,000-10,488,000-10,185,000-12,700,000-13,014,000-12,253,000-12,259,000-11,518,000-10,716,000-8,102,000-7,752,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-20.4%58.0073.0083.0096.0010770.0082.0094.0010611812838.0046.0054.0061.0068.0029.007.0014.0020.0026.00
  Current Assets-21.5%56.0072.0082.0094.0010568.0080.0092.0010511712536.0044.0052.0058.0065.0026.004.0011.0017.0023.00
    Cash Equivalents-22.3%55.0071.0081.0091.0010266.0078.0091.0010311512536.0043.0052.0052.0065.0025.004.0010.0016.0022.00
  Net PPE-100.0%-0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-16.5%11.0013.0011.0012.0011.0011.0012.0011.007.0010.0011.008.007.008.007.008.0011.009.009.009.009.00
  Current Liabilities-17.7%10.0013.0011.0012.0010.0011.0012.0010.007.0010.0011.008.007.007.007.007.009.008.008.008.008.00
Shareholder's Equity-21.2%47.0060.0072.0084.0028.0059.0070.0083.0099.0010811730.0038.0047.0053.0060.0018.00-6.0011.0017.00
  Retained Earnings-3.5%-413-399-387-373-360-318-306-290-273-263-252-241-232-222-216-209-202-195-187-179-170
  Additional Paid-In Capital0.3%461460458457388377375374373372370272271270269269220193192190188
Shares Outstanding0.1%26.0026.0026.0026.0013.0010.0011.0011.0011.006.008.008.00---------
Float----78.00---94.00---86,766,207---109---28.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-49.5%-15,516-10,380-10,488-10,185-12,700-13,014-12,253-12,259-11,518-10,716-8,102-7,752-8,587-5,988-6,592-9,451-3,926-5,894-6,957-7,183-6,868
  Share Based Compensation-0.4%1,2481,2531,3001,2651,3101,4571,2531,2661,2049381,003912833715670617570936950899947
Cashflow From Investing-----34849,317------------15.00---
Cashflow From Financing-29.00--1.00--29.00----21075597,2624.0014.00--38548,77725,605-19.001,2541,26012,322
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LPTX Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 11,299$ 38,942
General and administrative3,5263,784
Total operating expenses14,82542,726
Loss from operations(14,825)(42,726)
Interest income775848
Australian research and development incentives246272
Foreign currency loss(16)(307)
Change in fair value of Series X preferred stock warrant liability 50
Net loss$ (13,820)$ (41,863)
Net loss per share  
Basic (in dollars per share)$ (0.51)$ (3.24)
Diluted (in dollars per share)$ (0.51)$ (3.24)
Weighted average common shares outstanding  
Basic (in shares)27,014,10012,934,427
Diluted (in shares)27,014,10012,934,427

LPTX Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 54,921$ 70,643
Research and development incentive receivable738771
Prepaid expenses and other current assets526183
Total current assets56,18571,597
Property and equipment, net 5
Right of use assets, net577257
Research and development incentive receivable, net of current portion245 
Deferred costs39 
Deposits917966
Total assets57,96372,825
Current liabilities:  
Accounts payable5,9516,465
Accrued expenses4,0565,957
Lease liability - current portion430262
Total current liabilities10,43712,684
Non current liabilities:  
Lease liability, net of current portion154 
Total liabilities10,59112,684
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.001 par value; 240,000,000 shares authorized; 25,603,471 and 25,565,414 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively2626
Additional paid-in capital460,868459,591
Accumulated other comprehensive income (loss)(120)106
Accumulated deficit(413,402)(399,582)
Total stockholders' equity47,37260,141
Total liabilities and stockholders' equity$ 57,963$ 72,825
LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEleaptx.com
 INDUSTRYBiotechnology
 EMPLOYEES44

Leap Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Leap Therapeutics Inc? What does LPTX stand for in stocks?

LPTX is the stock ticker symbol of Leap Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Leap Therapeutics Inc (LPTX)?

As of Fri Jul 19 2024, market cap of Leap Therapeutics Inc is 78.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers. The fair value of Leap Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Leap Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LPTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Leap Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LPTX is over valued or under valued. Whether Leap Therapeutics Inc is cheap or expensive depends on the assumptions which impact Leap Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPTX.

What is Leap Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, LPTX's PE ratio (Price to Earnings) is -1.47 and Price to Sales (PS) ratio is 75.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPTX PE ratio will change depending on the future growth rate expectations of investors.